Indications
Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Composition
- Active substance
- avacopan
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tavneos
- Active substance
- avacopan
- ATC code
- L04
- Therapeutic area
- Microscopic Polyangiitis, Wegener Granulomatosis
- Marketing authorisation holder
- Vifor Fresenius Medical Care Renal Pharma France
- Status